Volume 7, Number 3—June 2001
Research
Melioidosis: An Emerging Infection in Taiwan?
Po-Ren Hsueh*, Lee-Jene Teng*, Li-Na Lee*†, Cheong-Ren Yu*, Pan-Chyr Yang*, Shen-Wu Ho*†, and Kwen-Tay Luh*
Table 2
Susceptibilities and antibiotypes of 17 isolates of Burkholderia pseudomallei isolated in Taiwan from November 1996 to January 2000
| MIC (μg/mL) a |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no./isolate | AM | AMC | PZP | CTX | CAZ | FEP | FLO | ATM | IPM | MEM | AN | CIP | TRO | MOX | Antibiotic type |
| 8/A | 64 | 8 | 0.5 | 4 | 4 | 16 | 128 | 16 | 0.5 | 1 | 64 | 2 | 2 | 2 | I |
| 9/B | 64 | 8 | 1 | 4 | 4 | 16 | 128 | 16 | 0.5 | 1 | 128 | 2 | 2 | 2 | I |
| 10/C1, 2 | 64 | 8 | 0.5 | 4 | 4 | 16 | 128 | 16 | 0.5 | 1 | 32 | 1 | 2 | 2 | II |
| 11/D1, 2, 3, 4, 5 | 64 | 8 | 0.5 | 2 | 1 | 16 | 128 | 16 | 0.5 | 1 | 32 | 2 | 4 | 1 | III |
| 12/E1, 2 | 64 | 8 | 0.5 | 2 | 1 | 8 | 128 | 16 | 0.5 | 1 | 32 | 2 | 4 | 1 | III |
| 13/F1, 2, 3 | 64 | 8 | 0.5 | 2 | 1 | 16 | 128 | 16 | 0.5 | 1 | 16 | 2 | 4 | 1 | III |
| 14/G | 16 | 2 | 0.12 | 2 | 1 | 8 | 64 | 8 | 0.25 | 0.5 | 64 | 1 | 1 | 1 | IV |
| 15/H1, 2 | 64 | 8 | 1 | 16 | 32 | 64 | 128 | 32 | 0.5 | 2 | >256 | 4 | 8 | 4 | V |
aAM, amoxicillin; AMC, amoxicillin-clavulanate; PZP, piperacillin-tazobactam; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; FLO, flomoxef; ATM, aztreonam; IPM, imipenem; MEM, meropenem; AN, amikacin; CIP, ciprofloxacin; TRO, trovafloxacin; MOX, moxifloxacin.
Page created: April 26, 2012
Page updated: April 26, 2012
Page reviewed: April 26, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.